Media Thread, page-8967

Thanks as always for sharing your experience, knowledge and thoughts here@Outlander2

I have a question if you don't mind indulging me re the FDA process. Do you think that we will need individual FDA IND approvals for each potential OnCARlytics partnership, ie; Arovella, Estrella and Cellularity or can we somehow piggyback off this approval?

It seems to me from my research that the combination with Amgen's Blincyto was the most promising of all the options so I can see why the team have gone down this path first, but the other potential partnerships also seem hugely exciting and the sooner we can move them all into human trials
the better.

Thanks mate!